{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:36:04Z","timestamp":1790030164105,"version":"4.0.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>We prospectively evaluated efficacy and safety of daptomycin versus active comparator in children with acute hematogenous osteomyelitis (AHO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Randomized, controlled, double-blind, global, multicenter, phase 3 trial. Patients 1\u201317 years of age with suspected\/confirmed AHO requiring hospitalization and intravenous therapy were randomized 1:1 to intravenous daptomycin (once-daily, age-adjusted doses) or comparator (vancomycin, nafcillin or equivalent) \u22654 days, followed by oral therapy (14\u201342 days total). Primary endpoint: protocol-defined clinical improvement by Day 5 in the modified intention-to-treat (MITT) population (confirmed AHO, \u22651 dose of study treatment); differences between study arms were evaluated using a prespecified 15% noninferiority margin for daptomycin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Seventy-three patients per arm received treatment. Pathogens were isolated from 62% of patients (83% methicillin-susceptible\n                      <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                      , 9% methicillin-resistant\n                      <jats:italic toggle=\"yes\">S. aureus<\/jats:italic>\n                      [MRSA]). Clinical improvement by Day 5 was observed in 55\/71 (78%) daptomycin- and 58\/70 (83%) comparator-treated MITT patients (95% confidence interval [CI]: \u221219.4, 7.4). This difference was not statistically significant; however, daptomycin did not meet the prespecified 15% noninferiority margin, since the lower bound of the 95% CI extended below 15%. Overall, 82% of daptomycin and 87% of comparator patients achieved clinical cure at the test-of-cure visit (secondary endpoint). More comparator patients had treatment-emergent (63% vs. 46%) and treatment-related (18% vs. 7%) adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Differences between daptomycin and comparator for the primary endpoint were not statistically significant; however, prespecified noninferiority criteria for daptomycin were not met. With insufficient cases of confirmed MRSA, we could not evaluate daptomycin for MRSA AHO. Our nonvalidated protocol design yields valuable information for implementing future trials in AHO (ClinicalTrials.gov NCT01922011).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000002790","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T23:25:50Z","timestamp":1594164350000},"page":"814-823","source":"Crossref","is-referenced-by-count":29,"title":["Daptomycin for Pediatric Gram-Positive Acute Hematogenous Osteomyelitis"],"prefix":"10.1097","volume":"39","author":[{"given":"John S.","family":"Bradley","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Rady Children\u2019s Hospital San Diego, San Diego, CA"},{"name":"Division of Pediatric Infectious Diseases, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio C.","family":"Arrieta","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Orange County, Orange, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeri A.","family":"Digtyar","sequence":"additional","affiliation":[{"name":"Dnipropetrovsk Regional Children\u2019s Clinical Hospital, Dnipropetrovsk, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myra W.","family":"Popejoy","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co, Inc., Kenilworth, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Grandhi","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co, Inc., Kenilworth, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Bokesch","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co, Inc., Kenilworth, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Hershberger","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co, Inc., Kenilworth, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Beth","family":"Dorr","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co, Inc., Kenilworth, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Tan","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co, Inc., Kenilworth, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Murata","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co, Inc., Kenilworth, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik J.","family":"Wolf","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co, Inc., Kenilworth, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mekki","family":"Bensaci","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, Merck & Co, Inc., Kenilworth, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,7,7]]},"reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/BPB.0000000000000441","article-title":"Nationwide survey of pediatric acute osteomyelitis in the USA.","volume":"26","author":"Okubo","year":"2017","journal-title":"J Pediatr Orthop B"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMra1213956","article-title":"Acute osteomyelitis in children.","volume":"370","author":"Peltola","year":"2014","journal-title":"N Engl J Med"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.3928\/00904481-20160428-01","article-title":"Acute hematogenous osteomyelitis in children.","volume":"45","author":"Whyte","year":"2016","journal-title":"Pediatr Ann"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3390\/ijms17060855","article-title":"Update on the management of pediatric acute osteomyelitis and septic arthritis.","volume":"17","author":"Castellazzi","year":"2016","journal-title":"Int J Mol Sci"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.ajem.2015.07.011","article-title":"Pediatric acute osteomyelitis in the postvaccine, methicillin-resistant Staphylococcus aureus era.","volume":"33","author":"Ratnayake","year":"2015","journal-title":"Am J Emerg Med"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"244","DOI":"10.5409\/wjcp.v5.i3.244","article-title":"Transitioning antimicrobials from intravenous to oral in pediatric acute uncomplicated osteomyelitis.","volume":"5","author":"Batchelder","year":"2016","journal-title":"World J Clin Pediatr"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/BPO.0b013e318186eb4b","article-title":"The impact of the current epidemiology of pediatric musculoskeletal infection on evaluation and treatment guidelines.","volume":"28","author":"Gafur","year":"2008","journal-title":"J Pediatr Orthop"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/INF.0b013e3181f55a89","article-title":"Short- versus long-term antimicrobial treatment for acute hematogenous osteomyelitis of childhood: prospective, randomized trial on 131 culture-positive cases.","volume":"29","author":"Peltola","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1469-0691.2011.03643.x","article-title":"Clindamycin vs. first-generation cephalosporins for acute osteoarticular infections of childhood\u2014a prospective quasi-randomized controlled trial.","volume":"18","author":"Peltola","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/01.inf.0000133044.79130.2a","article-title":"Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children.","volume":"23","author":"Mart\u00ednez-Aguilar","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1016\/j.ijid.2011.12.012","article-title":"Deep venous thrombosis in children with musculoskeletal infections: the clinical evidence.","volume":"16","author":"Mantadakis","year":"2012","journal-title":"Int J Infect Dis"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1542\/peds.2005-0566","article-title":"Panton-Valentine leukocidin genes are associated with enhanced inflammatory response and local disease in acute hematogenous Staphylococcus aureus osteomyelitis in children.","volume":"117","author":"Bocchini","year":"2006","journal-title":"Pediatrics"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2106\/JBJS.J.01915","article-title":"Pathologic fractures in children with acute Staphylococcus aureus osteomyelitis.","volume":"94","author":"Belthur","year":"2012","journal-title":"J Bone Joint Surg Am"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"18","DOI":"10.12968\/hmed.2015.76.1.18","article-title":"Panton-Valentine leukocidin osteomyelitis in children: a growing threat.","volume":"76","author":"Sheikh","year":"2015","journal-title":"Br J Hosp Med (Lond)"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1097\/BPO.0000000000001152","article-title":"Comparison of methicillin-resistant versus susceptible Staphylococcus aureus pediatric osteomyelitis.","volume":"38","author":"Davis","year":"2018","journal-title":"J Pediatr Orthop"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/BPO.0000000000000439","article-title":"Community-acquired methicillin-resistant Staphylococcus aureus musculoskeletal infections: emerging trends over the past decade.","volume":"36","author":"Sarkissian","year":"2016","journal-title":"J Pediatr Orthop"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.idc.2015.05.012","article-title":"Osteoarticular infections in children.","volume":"29","author":"Arnold","year":"2015","journal-title":"Infect Dis Clin North Am"},{"key":"R19-20230912","first-page":"47","article-title":"Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections.","volume":"9","author":"Gonzalez-Ruiz","year":"2016","journal-title":"Infect Drug Resist"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"e20162477","DOI":"10.1542\/peds.2016-2477","article-title":"Daptomycin for complicated skin infections: a randomized trial.","volume":"139","author":"Bradley","year":"2017","journal-title":"Pediatrics"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/INF.0000000000001926","article-title":"Randomized multicenter study comparing safety and efficacy of daptomycin versus standard-of-care in pediatric patients with Staphylococcal bacteremia.","volume":"37","author":"Arrieta","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1128\/AAC.02344-14","article-title":"Penetration of daptomycin into bone and synovial fluid in joint replacement.","volume":"58","author":"Montange","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ijantimicag.2017.12.011","article-title":"Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011\u20132016).","volume":"51","author":"Pfaller","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.diagmicrobio.2017.03.003","article-title":"Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations.","volume":"88","author":"Jones","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R25-20230912","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/jac\/dki435","article-title":"Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis.","volume":"57","author":"Rouse","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12941-016-0130-8","article-title":"Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE.","volume":"15","author":"Seaton","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/INF.0000000000001076","article-title":"Clinical experience with daptomycin for the treatment of Gram-positive infections in children and adolescents.","volume":"35","author":"Syriopoulou","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R28-20230912","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10096-015-2515-6","article-title":"Daptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registry.","volume":"35","author":"Malizos","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/jpids\/piw048","article-title":"Clinical effectiveness, safety profile, and pharmacokinetics of daptomycin in pediatric patients: a systematic review.","volume":"5","author":"Karageorgos","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/00007611-198202000-00005","article-title":"Clindamycin versus nafcillin or methicillin in the treatment of Staphylococcus aureus osteomyelitis in children.","volume":"75","author":"Kaplan","year":"1982","journal-title":"South Med J"},{"key":"R31-20230912","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijid.2004.09.009","article-title":"Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials?","volume":"9","author":"Lazzarini","year":"2005","journal-title":"Int J Infect Dis"},{"key":"R32-20230912","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/01.bpo.0000242431.91489.b4","article-title":"Changing patterns of acute hematogenous osteomyelitis and septic arthritis: emergence of community-associated methicillin-resistant Staphylococcus aureus.","volume":"26","author":"Arnold","year":"2006","journal-title":"J Pediatr Orthop"},{"issue":"suppl 1","key":"R33-20230912","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.jinf.2013.09.014","article-title":"Recent lessons for the management of bone and joint infections.","volume":"68","author":"Kaplan","year":"2014","journal-title":"J Infect"},{"key":"R34-20230912","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/INF.0000000000001753","article-title":"Analysis of invasive community-acquired methicillin-susceptible Staphylococcus aureus infections during a period of declining community acquired methicillin-resistant Staphylococcus aureus infections at a large children\u2019s hospital.","volume":"37","author":"Hult\u00e9n","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"R35-20230912","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12879-017-2271-6","article-title":"Decline in the proportion of methicillin resistance among Staphylococcus aureus isolates from non-invasive samples and in outpatient settings, and changes in the co-resistance profiles: an analysis of data collected within the Antimicrobial Resistance Surveillance Network, Germany 2010 to 2015.","volume":"17","author":"Walter","year":"2017","journal-title":"BMC Infect Dis"},{"key":"R36-20230912","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/01241398-199905000-00025","article-title":"Community-acquired methicillin-resistant Staphylococcus aureus: a cause of musculoskeletal sepsis in children.","volume":"19","author":"Gwynne-Jones","year":"1999","journal-title":"J Pediatr Orthop"},{"key":"R40-20230912","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/BPO.0b013e3181ab472d","article-title":"Prospective evaluation of a shortened regimen of treatment for acute osteomyelitis and septic arthritis in children.","volume":"29","author":"Jagodzinski","year":"2009","journal-title":"J Pediatr Orthop"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002790","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T19:04:44Z","timestamp":1694545484000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,7]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002790","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,7]]}}}